Esaprazole effect on acid, peptic and alkaline secretion in duodenal ulcer patients.
To study the effect of Esaprazole, a new antiulcer drug, on acid, peptic and alkaline secretion a modified gastric acid test was performed in 18 duodenal ulcer patients. Pentagastrin was administered as bolus 30' and 75' after the beginning of the test, followed by Esaprazole 300 mg i.v. at 90'. Gastric juice was collected every 15' for determination of: total volume, volume of non parietal secretion, acid, bicarbonate and pepsin output. Serum pepsinogen group I was determined by radioimmunoassay. Esaprazole had a significant inhibitory effect on the total volume of gastric secretion and on volume of non parietal secretion. Pepsin output and serum pepsinogen group I were not affected by Esaprazole, while bicarbonate secretion was reduced. Antiulcer activity of Esaprazole seems to be due to the reduction of total volume of gastric secretion.
Dal Santo
P L
PL
Istituto di Medicina Interna Cattedra Malattie Apparato Digerente Università degli Studi di Padova, Italia.
Vianello
F
F
Germana
B
B
Dotto
P
P
Laino
G
G
Del Bianco
T
T
Plebani
M
M
Leandro
G
G
Savarino
V
V
Di Mario
F
F
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001639:Bicarbonates / Q000378:metabolism*; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005750:Gastric Juice / Q000187:drug effects* / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin; D010435:Pepsinogens / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D001639:Bicarbonates; D010435:Pepsinogens; D010879:Piperazines; C042123:esaprazole; D010418:Pentagastrin